123 related articles for article (PubMed ID: 9284083)
1. Metabolism of administered triethylene tetramine dihydrochloride in humans.
Kodama H; Murata Y; Iitsuka T; Abe T
Life Sci; 1997; 61(9):899-907. PubMed ID: 9284083
[TBL] [Abstract][Full Text] [Related]
2. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
3. Triethylene-tetramine (trien) therapy for Wilson's disease.
Saito H; Watanabe K; Sahara M; Mochizuki R; Edo K; Ohyama Y
Tohoku J Exp Med; 1991 May; 164(1):29-35. PubMed ID: 1926144
[TBL] [Abstract][Full Text] [Related]
4. Low copper and brain abnormalities in fetus from triethylene tetramine dihydrochloride-treated pregnant mouse.
Tanaka H; Yamanouchi M; Imai S; Hayashi Y
J Nutr Sci Vitaminol (Tokyo); 1992 Dec; 38(6):545-54. PubMed ID: 1304599
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
Walshe JM
Lancet; 1982 Mar; 1(8273):643-7. PubMed ID: 6121964
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of excretion of trientine from the rat kidney: trientine is not recognized by the H+/organic cation transporter.
Kobayashi M; Tanabe R; Sugawara M; Iseki K; Miyazaki K
J Pharm Pharmacol; 1997 Apr; 49(4):426-9. PubMed ID: 9232542
[TBL] [Abstract][Full Text] [Related]
7. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance.
Gibbs K; Walshe JM
Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055
[TBL] [Abstract][Full Text] [Related]
8. Tetramine cupruretic agents: a comparison in dogs.
Allen KG; Twedt DC; Hunsaker HA
Am J Vet Res; 1987 Jan; 48(1):28-30. PubMed ID: 3826839
[TBL] [Abstract][Full Text] [Related]
9. Acquired sideroblastic anaemia induced by a copper-chelating agent.
Perry AR; Pagliuca A; Fitzsimons EJ; Mufti GJ; Williams R
Int J Hematol; 1996 Jul; 64(1):69-72. PubMed ID: 8757970
[TBL] [Abstract][Full Text] [Related]
10. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson's disease.
Kodama H; Meguro Y; Tsunakawa A; Nakazato Y; Abe T; Murakita H
Tohoku J Exp Med; 1993 Jan; 169(1):59-66. PubMed ID: 8211970
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of copper, zinc and iron with and without D-penicillamine administration in relation to hepatic copper concentration in dogs.
Fieten H; Hugen S; van den Ingh TS; Hendriks WH; Vernooij JC; Bode P; Watson AL; Leegwater PA; Rothuizen J
Vet J; 2013 Aug; 197(2):468-73. PubMed ID: 23583003
[TBL] [Abstract][Full Text] [Related]
12. Triethylene tetramine dihydrochloride toxicity in primary biliary cirrhosis.
Epstein O; Sherlock S
Gastroenterology; 1980 Jun; 78(6):1442-5. PubMed ID: 6445305
[TBL] [Abstract][Full Text] [Related]
13. Effect of metal chelators on excretion and tissue levels of essential trace elements.
Tandon SK; Jain VK; Mathur AK
Environ Res; 1984 Oct; 35(1):237-45. PubMed ID: 6436015
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
Haslam RH; Sass-Kortsak A; Stout W; Berg M
Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
[TBL] [Abstract][Full Text] [Related]
15. Teratogenic effects of triethylene tetramine dihydrochloride on the mouse brain.
Tanaka H; Inomata K; Arima M
J Nutr Sci Vitaminol (Tokyo); 1993 Apr; 39(2):177-88. PubMed ID: 8410376
[TBL] [Abstract][Full Text] [Related]
16. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
Lu J; Chan YK; Gamble GD; Poppitt SD; Othman AA; Cooper GJ
Drug Metab Dispos; 2007 Feb; 35(2):221-7. PubMed ID: 17108057
[TBL] [Abstract][Full Text] [Related]
17. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
Walshe JM
Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
[No Abstract] [Full Text] [Related]
18. Effects of some chelating agents on urinary copper excretion by the rat.
Jones MM; Singh PK; Zimmerman LJ; Gomez M; Albina ML; Domingo JL
Chem Res Toxicol; 1995; 8(7):942-8. PubMed ID: 8555409
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride.
Sone K; Maeda M; Wakabayashi K; Takeichi N; Mori M; Sugimura T; Nagao M
Hepatology; 1996 Apr; 23(4):764-70. PubMed ID: 8666330
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of trientine, a copper-chelating agent, on induction of DNA strand breaks in kidney cells of Long-Evans Cinnamon (LEC) rats.
Hayashi M; Miyane K; Senou M; Endoh D; Higuchi H; Nagahata H; Nakayama K; Kon Y; Okui T
Exp Anim; 2005 Oct; 54(5):403-12. PubMed ID: 16365517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
